Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arovella Therapeutics Limited ( (AU:ALA) ) has issued an update.
Arovella Therapeutics Limited has issued 1,013,333 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, complying with all relevant provisions. This move reflects the company’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies, potentially enhancing its market presence and stakeholder value.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company focused on developing invariant natural killer T (iNKT) cell therapy platforms to treat blood cancers and solid tumors. Their lead product, ALA-101, uses CAR19-iNKT cells targeting CD19, an antigen present on various cancer types, and is developed as an allogeneic cell therapy. Arovella is also advancing into solid tumor treatments with CLDN18.2-targeting technology and IL-12-TM technology.
Average Trading Volume: 1,415,469
Technical Sentiment Signal: Sell
Current Market Cap: A$106.7M
See more insights into ALA stock on TipRanks’ Stock Analysis page.